vb10.16
Vaccineexperimental
Clinical trial activity
4 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2015 (NCT02529930)
Timeline
Indications
Mechanism of action
- Human papillomavirusImmunity, active
Human papillomavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vb10.16
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06099418 | Phase 2 | Dec 31, 2023 | GOG Foundation, Inc., Nykode Therapeutics ASA, Roche |
| NCT06016920 | Phase 1/Phase 2 (Phase 2) | Dec 19, 2023 | Merck, Nykode Therapeutics ASA, University of Oslo |
| NCT04405349 | Phase 2 | May 31, 2020 | Roche, Vaccibody AS |
| NCT02529930 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2015 | Theradex, Vaccibody AS |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nykode Therapeutics ASA | For profit | 2 | 2 | 1 | 2023 |
| Roche | For profit | 2 | 0 | 1 | 2020 |
| Vaccibody AS | For profit | 2 | 2 | 1 | 2015 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
| Theradex | For profit | 1 | 0 | 1 | 2015 |
| University of Oslo | Academic/Hospital | 1 | 0 | 1 | 2023 |
7 organizations
Page 1 / 1